Modality
ADC
MOA
WEE1i
Target
CD3
Pathway
Neuroinflam
Bladder CaGAAngelman
Development Pipeline
Preclinical
Oct 2025
→ Jan 2025
PreclinicalCurrent
NCT05236630
308 pts·Bladder Ca
2025-10→2025-01·Terminated
308 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-121.2y agoInterim· Bladder Ca
Trial Timeline
2025Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2025-01-12 · 1.2y ago
Bladder Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05236630 | Preclinical | Bladder Ca | Terminated | 308 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| Cevicapivasertib | Corcept | Phase 2 | CFTR |